Disappointment: one of the covid treatments “did not give the expected result”

The Swiss pharmaceutical group Novartis announced today that clinical trials with ruxolitinib for him coronavirus treatment did not show improvement in severe cases, “They did not give the expected result.”

“The phase 3 study (the last phase of human trials) did not give the expected result reduction in the number of hospitalizations patients with covid-19 with serious complications (death, mechanical ventilation or intensive care), ”said this group in a press release quoted by AFP.

“Although the clinical trial with Ruxcovid did not give the expected results, we will continue to work with the medical community to analyze the results and better understand the Covid-19 and inhibition of Janus kinase “(a family of enzymes), said John Tsai, Novartis medical director and drug developer.

The group points out that the fact that Ruxcovid does not work to improve the situation of patients Covid-19 “does not affect ongoing trials on other diseases” to the new coronavirus.

he ruxolitinib is already marketed for other indications, under the name Javaki.